In patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF), the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of worsening HF or cardiovascular death by 18%, reduces total HF events and cardiovascular deaths by 23% and improves HF symptoms, according to findings from the DELIVER trial presented at the ESC Congress 2022. Moreover, the findings were similar regardless of ejection fraction or care setting (outpatient or inpatient) and in patients with HF with improved ejection fraction (those who had previously had a left ventricular ejection fraction (LVEF) of ≤40% that had risen to >40%). “These data should establish SGLT2 inhibitors as foundational therapy in HF irrespective of care setting or ejection fraction,” says the trial lead investigator, Scott Solomon.